Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet a...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2010-09-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://www.dia-endojournals.ru/jour/article/view/5489 |